Posted by Michael Wonder on 21 Apr 2021
Health economic assessment of Qarziba in patients with high-risk neuroblastoma
21 April 2021 - TLV has produced a health economic assessment for the regions for the drug Qarziba (dinutuximab beta).
TLV has evaluated Qarziba as the first-line treatment for so-called high-risk neuroblastoma in patients aged 12 months and older.
